Redeye returns with an updated take on 2cureX following TICC trial result publication. Following this successful proof-of-concept, the company is now ready for IndiTreat commercialization in metastatic colorectal cancer. Reassessing its commercial outlook and our financial estimates, we have updated our fair value range.